Table 5.
Adjusted multivariate analysis investigating the association between interventional telemonitoring (ITM) and cardiovascular mortality compared to other study groups.
| ORa | 95% CI | P-value | |
|---|---|---|---|
| Age | 1.036 | (0.997–1.077) | 0.069 |
| Hypertension | 0.615 | (0.261–1.451) | 0.267 |
| Diabetes mellitus | 1.047 | (0.411–2.668) | 0.923 |
| Ischemic-HF | 0.990 | (0.437–2.241) | 0.981 |
| LVEF | 0.927 | (0.887–0.970) | 0.001 |
| Ivabradine use | 0.309 | (0.038–2.532) | 0.274 |
| (ACEi, ARB, ARNIs) | 0.584 | (0.226–1.508) | 0.267 |
| Ambulatory process | 1.677 | (0.405–6.933) | 0.476 |
| Groups | |||
| -STM-group | 1.986 | (0.768–5.134) | 0.157 |
| -ITM-group | 0.322 | (0.103–1.012) | 0.052 |
STM-group, standard telemonitoring-group; ITM-group, interventional telemonitoring group; BMI, body mass index; HF, heart failure; LVEF, left ventricular ejection fraction; ACEi, Angiotensin converting enzyme inhibitor; ARB, Angiotensinogen 2 receptor antagonist; ARNIs, Angiotensin receptor-neprilysin inhibitors; ORa, adjusted odds ratios.